drugset / Trial / NCT04753203
Alpelisib and Capecitabine in Patients With PIK3CA Mutant mCRC Patients
NaSingle-groupOpen-labelTreatment
Summary
The investigator assesses the efficacy and safety of alpelisib and capecitabine in patients with PIK3CA mutant metastatic colorectal cancer who failed two prior standard chemotherapies.
Timeline
- Start
- 2021-02-28
- Primary completion
- 2024-02-28
- Completion
- 2025-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Alpelisib | Small molecule | — | — |
| Subject | Capecitabine | Small molecule | — | — |